Navigation Links
McMaster study unveils lifeline for 'antibiotic of last resort'
Date:4/11/2010

Hamilton, ON (April 9, 2010) A new study led by the scientific director of the Michael G. DeGroote Institute for Infectious Disease Research has uncovered for the first time how bacteria recognize and develop resistance to a powerful antibiotic used to treat superbug infections.

Gerry Wright, a professor in the Department of Biochemistry and Biomedical Sciences at McMaster University in collaboration with colleagues at the John Innes Centre in Norwich, and the University of Cambridge in the UK, have identified the specific mechanism that triggers resistance to vancomycin.

The discovery reveals new understanding about what is happening at the molecular level in vancomycin resistance. It also represents an essential first step in developing new antibiotics that can evade the sensing mechanism of bacteria and overcome resistance.

The research, funded in part by the Canadian Institutes of Health Research and the Canada Research Chairs program, will be published online in the high-impact journal Nature Chemical Biology on April 11, 2010.

"Vancomycin is the antibiotic of last resort and is only given when all other treatments fail," said Wright, who holds the Canada Research Chair in Molecular Studies of Antibiotics and an endowed research Chair in Infection and Anti-Infective Research.

"For years it was thought that resistance would be slow to emerge since vancomycin works in an unusual way. But with the widespread use of the drug to treat infections caused by the hospital superbug MRSA, it has become a serious clinical problem."

MRSA is the short-form for methicillin-resistant staphylococcus aureus, a bacterial infection that is highly resistant to some antibiotics. MRSA bacteria are responsible for a large percentage of hospital-acquired staph infections, but may also be acquired in the community.

Vancomycin is used to treat enterococcal infections that develop in patients following abdominal surgery. Enterococcal bacteria first developed resistance to vancomycin in 1986 and the first case of vancomycin-resistant MRSA (VMRSA) was reported in 2002.

For 20 years, scientists around the world have debated whether bacteria sense the drug itself to trigger resistance or whether they sense the impact it has on the cell wall of bacteria.

Most antibiotics work by inhibiting an enzyme but vancomycin binds to cell wall building blocks, causing a weakness in the structure of the cell wall so the cell bursts and dies.

Some scientists believed that bacteria detect the cell wall degradation to trigger resistance. Others argued that bacteria detect the presence of the drug directly.

Wright and his team studied the vancomycin-resistance mechanism in the harmless soil bacteria Streptomyces coelicolor.

The scientists showed that bacteria detect vancomycin itself. They also conducted preliminary experiments that suggest the same mechanism exists in disease causing bacteria.

"We have finally cracked the alarm system used by bacteria, and hopefully new antibiotics can be developed that don't set it off," said Mark Buttner, a study collaborator and senior scientist at the John Innes Centre.

Marc Ouellette, scientific director of the Institute of Infection and Immunity at the Canadian Institutes for Health Research (CIHR), said the research findings shed new light on the antibiotic resistance issue.

"Thousands of Canadians die every year from antibiotic-resistant infections," Ouellette said. "This issue has long been a priority of the CIHR and this exciting work expands our understanding of how bacteria develop resistance to antibiotics. It lays the groundwork for developing new therapies to prevent and treat antibiotic-resistant infections."


'/>"/>

Contact: Susan Emigh
emighs@mcmaster.ca
905-518-3642
McMaster University
Source:Eurekalert

Related biology news :

1. New research network at McMaster aims to build a better eye
2. McMaster researchers discover new mode of how diseases evolve
3. McMaster University engineering professor receives Humboldt Research Award
4. FSU marine ecologist wins grant to study endangered sawfish
5. Pitt-led international study identifies human enzyme that breaks down potentially toxic nanomaterials, opens door to novel drug delivery
6. Pitt-led study identifies human enzyme that breaks down potentially toxic nanomaterials
7. BUSPH study links rheumatoid arthritis to vitamin D deficiency
8. 4,000-year study supports use of prescribed burns in Southern Appalachians
9. New study shows rising water temperatures in US streams and rivers
10. MSU leads global effort to study link between people, planet
11. Peregrine reports new study from Duke shows anti-HIV potential of targeting PS on cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/14/2016)... CLARA, Calif. , Nov. 14, 2016 ... the biometric identification market, Frost & Sullivan ... Frost & Sullivan Award for Visionary Innovation ... player in the biometric identification market by ... multi-modal verification solution for instant, seamless, and ...
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016 Savannah River Remediation ... and selected NewTechBio,s NT-MAX Lake & Pond ... beneficial bacteria, in conjunction with Hexa Armor/ Rhombo ... with National Pollutant Discharge Elimination System requirements. ... a steady history of elevated pH levels, above ...
(Date:12/7/2016)... ... 2016 , ... ACEA Biosciences, Inc. presented today updated efficacy ... for its lead drug candidate, AC0010, at the World Conference on Lung Cancer ... the safety, antitumor activity, and recommended phase II dosage of AC0010 in T790M-postitive ...
(Date:12/7/2016)... /PRNewswire/ - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical company ... products for the treatment of cancer, today announced ... Development Program with Cytovance Biologics ( Oklahoma ... antibody product. Supported by recent positive interim clinical ... ovarian cancer patients, OncoQuest has engaged Cytovance to ...
(Date:12/7/2016)... 2016 The report "Acrylic Processing Aid Market by Polymer Type (PVC), ... Goods) - Global Forecast to 2026", published by MarketsandMarkets, the global market size ... Million by 2026, registering an of CAGR of 6.2% between 2016 and 2026. ... ... MarketsandMarkets Logo ...
Breaking Biology Technology: